LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN TRUE NORTH WEEK 52 CLINICAL REMITTERS OVER 3 YEARS OF TREATMENT WITH OZANIMOD: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Remo Panaccione  ¹     David T. Rubin  ²     Maria T. Abreu  ³     Michael Chiorean  ⁴     Lucy Akukwe  ⁵     Anjali Jain  ⁵     AnnKatrin Petersen  ⁵     Mark T. Osterman  ⁵     Hsiuanlin Wu  ⁵     Silvio Danese  ⁶     Anita Afzali  ^7    
1 Inflammatory Bowel Disease Clinic, Calgary, Alberta, Canada
² University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States
³ University of Miami Miller School of Medicine, Miami, United States
⁴ Swedish Medical Center, Seattle, United States
⁵ Bristol Myers Squibb, Princeton, United States
⁶ Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
⁷ Division of Digestive Diseases, University of Cincinnati, Cincinnati, United States

Topic
IBD

Session
Targeting immune cell trafficking in IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)